Our aim in this study was to evaluate the relationship between pathological and clinical risk classifications in newly diagnosed prostate cancer patients and 68Ga-PSMA PET/CT data and serum Prostate Specific Antigen (PSA) values. This evidence concerns the gene FOLH1 and Familial prostate cancer.